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Abstract
Aberrations in the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway are common
abnormalities in breast cancer and are associated with the development of resistance to endocrine- and human
epidermal growth factor receptor (HER)2-targeted therapies. Because of the signiﬁcant improvement in progression-
free survival for everolimus plus exemestane compared with exemestane plus placebo, everolimus, an mTOR inhibitor,
was approved in the United States for the treatment of patients with hormone receptor-positive (HRþ), HER-negative,
advanced breast cancer whose disease had progressed while receiving letrozole or anastrozole. To provide optimal
prevention and management strategies, it is crucial that clinicians are aware of the adverse events (AEs) associated
with mTOR inhibition. Understanding the appropriate dose modiﬁcations will help reduce toxicity and improve drug
tolerance, thus achieving the optimal beneﬁt from everolimus. Analyses of data from the Breast Cancer Trials of Oral
Everolimus 2 trial have shown that, despite a greater frequency of AEs in the everolimus plus exemestane treatment
arm, the AEs were effectively managed with temporary dose reductions or interruptions. In some cases, the full dose of
everolimus could be resumed. Despite a lower mean dose and duration of exposure in patients aged  70 versus < 70
years, everolimus plus exemestane was similarly efﬁcacious, suggesting that appropriate dose reductions for toxicity
will not adversely impact efﬁcacy. Appropriate modiﬁcation of the everolimus dose and dose delay according to the
severity of AEs, with resumption of the optimal dose of everolimus when toxicity has improved, will positively affect
patient outcomes in HRþ advanced breast cancer.
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Breast cancer is the second most common cancer (age-stan-
dardized incidence rate, 76.0 per 100,000) and the second-leading
cause of cancer-related death (age-standardized mortality rate,
14.7 per 100,000) among US adults.1 In the United States in 2015,
> 230,000 women will have been diagnosed with breast cancer and
approximately 40,000 will have died of their disease.2 Approxi-
mately 60% to 75% of patients with invasive breast cancer have
hormone receptor-positive (HRþ), human epidermal growth factor
receptor 2 (HER2)-negative disease.3,4 These cancers are commonlyUniversity of California, San Francisco, Helen Diller Family Comprehensive Cancer
Center, San Francisco, CA
Submitted: Jun 16, 2015; Accepted: Sep 11, 2015; Epub: Sep 29, 2015
Address for correspondence: Hope S. Rugo, MD, University of California, San Fran-
cisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 2nd
Floor, Box 1710, San Francisco, CA 94115
E-mail contact: hope.rugo@ucsf.edu
Clinical Breast Cancer February 2016
1526-8209/ª 2016managed with endocrine therapies such as aromatase inhibitors (eg,
anastrozole, letrozole, and exemestane), selective estrogen receptor
modulators (eg, tamoxifen and toremifene), and, in the advanced
setting, the estrogen receptor downregulator fulvestrant.5
Aberrations in the phosphoinositide 3-kinase/protein kinase B/
mammalian target of rapamycin (PI3K/AKT/mTOR) pathway are
common in breast cancer,6-9 with activating mutations in PIK3CA
present in one quarter to one half of HRþ breast tumors.7,8 Current
data suggest that the frequency of abnormalities in this pathway
is more common in metastatic than in primary tumors.10 Also,
increased signaling through this pathway has been associated with
resistance to endocrine and HER2-targeted therapies.11-14 Thus,
targeting the PI3K/AKT/mTOR pathway is an appealing treatment
strategy.
Several mTOR inhibitors have been investigated as antitumor
therapies, with 2 agents (everolimus and temsirolimus) currently
approved by the US Food and Drug Administration (FDA) for the
treatment of various cancers.15,16 Upstream pathway inhibitorsThe Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
targeting PI3K are under evaluation, with several now being tested in
the clinic.17 The cyclin-dependent kinase (CDK) 4/6 inhibitor pal-
bociclib, which targets the cell cycle, recently received accelerated
FDA approval for the treatment of HRþ advanced breast cancer
combinedwith letrozole based on the results of a recent phase II study,
which demonstrated a signiﬁcant improvement in progression-free
survival (PFS) with this combination.18 Agents targeting other
pathways and other CDK 4/6 inhibitors are under investigation in
breast cancer clinical trials in combination with hormone therapies.19
Everolimus is the onlymTOR inhibitor indicatedwith approval for
use combined with exemestane for the treatment of patients with
HRþ HER2 advanced breast cancer whose disease has progressed
during treatment with letrozole or anastrozole.15 This approval was
based on the results from interim and ﬁnal analyses of the robust phase
III Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2) study in
which everolimus plus exemestane was associated with a signiﬁcant
improvement in investigator-determined PFS (primary endpoint)
compared with exemestane plus placebo in postmenopausal women
withHRþ advanced breast cancer who had experienced recurrence or
progression during or soon after nonsteroidal aromatase inhibitor
(NSAI) therapy.20,21 At amedian follow-up period of 18months, PFS
had more than doubled among those receiving everolimus plus
exemestane versus those receiving exemestane plus placebo (7.8 vs.
3.2 months; hazard ratio, 0.45; 95% conﬁdence interval, 0.38-0.54;
P< .0001).21 In addition, the relative reduction in risk of PFS events
with the addition of everolimus to exemestane was evident in both
younger and older age groups (56% and 55% in those aged < 70
and  70 years, respectively).22
In the overall survival (OS) analyses, the addition of everolimus
to exemestane resulted in the longest OS reported to date in the
post-NSAI setting23-25; however, a statistically signiﬁcant survival
beneﬁt compared with exemestane alone was lacking (31.0 vs. 26.6
months; hazard ratio, 0.89; 95% conﬁdence interval, 0.73-1.10;
P ¼ .14).23 This lack of signiﬁcance could have resulted from
several factors. First, BOLERO-2 was not sufﬁciently powered to
detect an OS advantage of less than an optimistic 8 months. Second,
differences existed between the study arms with respect to the post-
study use of salvage chemotherapy, making survival effects difﬁcult
to demonstrate. In addition, it has been historically challenging to
demonstrate a survival beneﬁt in patients with HRþ advanced
breast cancer receiving endocrine therapy. Signiﬁcant OS beneﬁts
have been restricted to trials of ﬁrst-line therapies for advanced
disease.23 However, despite these potential confounding factors, a
lower proportion of deaths in BOLERO-2 occurred in the ever-
olimus plus exemestane group than in the exemestane plus placebo
group (55.1% vs. 59.8%, respectively), suggesting a possible sur-
vival beneﬁt with the concurrent use of everolimus.23
The class-effect toxicities associated with mTOR inhibitors are
well characterized and include epithelial-cutaneous adverse events
(AEs; eg, stomatitis, rash), pulmonary dysfunction (eg, noninfec-
tious pneumonitis), metabolic AEs (eg, hyperglycemia, hyperlipid-
emia), and fatigue.26 The lack, or inappropriate management, of
these toxicities can potentially compromise the therapeutic effec-
tiveness of mTOR inhibitors, such as everolimus.26 Everolimus is
generally well tolerated in the treatment of advanced breast cancer,
with its most common AEs stomatitis, infections, rash, noninfec-
tious pneumonitis, fatigue, hyperglycemia, hyperlipidemia, andmyelosuppression. Most of these AEs are not life-threatening and
can be resolved by dose interruptions or adjustments.26,27 This
point was supported for stomatitis, in particular, through a recent
meta-analysis of randomized, controlled, phase III trials in patients
with advanced solid tumors, including trials of advanced breast
cancer, advanced pancreatic neuroendocrine tumor, and advanced
renal cell carcinoma. This demonstrated that the efﬁcacy of ever-
olimus (in regard to PFS) was maintained despite the development
of stomatitis and the need for dose reductions or interruptions to
manage this common everolimus-related toxicity.28
To provide the most effective prevention and management
strategies, it is important that practitioners and patients are familiar
with the AEs associated with mTOR inhibition. Optimal dosing is
important to achieve maximum therapeutic efﬁcacy with appro-
priate drug exposure and maintain patient quality of life. The pre-
sent report reviews the implications of currently available
BOLERO-2 data on everolimus dose intensity, exposure, and
safety in treating patients with advanced breast cancer.
Dose Intensity and Exposure
In the BOLERO-2 trial, the median duration of exposure to
everolimus was 23.9 weeks (range, 1.0-123.3 weeks) at a median
follow-up period of 18 months,21 and the median dose intensity of
everolimus was 8.6 mg/day.29 Drug exposure was affected by age.
Comparedwith patients aged< 70 years, themedian dose intensity of
everolimuswhen administered with exemestane was lower for patients
aged  70 years (8.9 vs. 7.2 mg/day), with a decrease in the mean
duration of exposure of both everolimus (33.8 vs. 23.2 weeks) and
exemestane (36.1 vs. 27.4 weeks) when these drugs were administered
in combination.22 Overall, 46.1% of patients in the everolimus plus
exemestane treatment arm had a relative everolimus dose intensity of
0.9 to< 1.1, 18.9% had a relative dose intensity of 0.7 to< 0.9, and
17.0% had a relative dose intensity of 0.5 to < 0.7.30
Dose Reductions and Interruptions Because of AEs
AEs of any grade were more common in patients treated with
everolimus plus exemestane than in those treated with exemestane
plus placebo (100% vs. 91%), as were grade 3 AEs (44% vs. 23%).
However, grade 4 AEs (9% vs. 6%) were uncommon, regardless of
the assigned treatment.29 In the everolimus plus exemestane arm,
the most common AEs of any grade were stomatitis (59%), rash
(39%), fatigue (37%), diarrhea (34%), nausea (31%), and decreased
appetite (31%). The most common grade 3 events were stomatitis
(8%), anemia (7%), dyspnea (5%), an increase in gamma-glutamyl
transferase (5%), hyperglycemia (5%), and fatigue (4%).21 Pneu-
monitis was also more common in everolimus plus exemestane arm
than in the exemestane plus placebo arms (all grades, 16% vs. 0%;
grade 3, 3% vs. 0%).21
Dose reductions or interruptions were required in 301 patients
(62%) treated with everolimus plus exemestane and in 28 patients
(12%) treated with exemestane plus placebo.29 A total of 1065
everolimus dose-interruption or dose-reduction events were re-
ported in the BOLERO-2 trial, with 44% of these events resolving
and allowing resumption of full-dose everolimus (10 mg/day) and
76% 1 within 2 weeks (Table 1).29 For everolimus, 705 dose in-
terruptions and 360 dose reductions were required.29 The median
duration of dose reduction for everolimus was 29 days (range, 1-672Clinical Breast Cancer February 2016 - 19
Table 1 Dose Reductions and Interruptions Due to Adverse Events in the BOLERO-2 Trial29
Variable
EVE D EXE (n [ 482) PBO D EXE (n [ 238)
Total (n) EVE EXE Total (n) PBO EXE
1 Dose reduction
Patients aged <65 years 290 101 (35) 0 158 4 (3) 0
Patients aged 65-69 years 74 35 (47) 0 37 1 (3) 0
Patients aged 70 years 118 45 (38) 1 (<1) 43 2 (5) 0
Previous chemotherapy 29 8 (28) 1 (3) 14 1 (7) 0
Previous endocrine therapy 434 166 (38) 0 214 6 (3) 0
1 Dose interruption
Patients aged <65 years 290 159 (55) 35 (12) 158 16 (10) 7 (4)
Patients aged 65-69 years 74 42 (57) 10 (14) 37 5 (14) 3 (8)
Patients aged 70 years 118 68 (58) 28 (24) 43 3 (7) 3 (7)
Previous chemotherapy 29 17 (59) 5 (17) 14 1 (7) 0
Previous endocrine therapy 434 240 (55) 63 (15) 214 22 (10) 12 (6)
Data presented as n or n (%).
Abbreviations: BOLERO-2 ¼ Breast Cancer Trials of Oral Everolimus-2; EVE ¼ everolimus; EXE ¼ exemestane; PBO ¼ placebo.
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20 -days), and the median duration of dose interruption for everolimus
was 7 days (range, 1-41 days).29 For patients receiving everolimus
plus exemestane,  1 dose interruption for AEs was required for
everolimus in 56% and for exemestane in 15%. The corresponding
proportions were 10% and 5% for placebo and exemestane.29 Pa-
tient age, previous exposure to chemotherapy, and previous endo-
crine therapy did not inﬂuence the requirement for dose
interruptions or reductions (Table 2).29
In general, a dose interruption has been recommended for grade
3 toxicities, with resumption of treatment either at a lower dose or
at the same dose (depending on the speciﬁc toxicity) after recovery
to grade  1. Class-effect AEs in the everolimus plus exemestane
treatment arm generally resolved quickly and completely after dose
interruption or reduction. Thus, 38 of 39 patients (97%) with
grade  3 stomatitis experienced resolution to grade  1 after a
median of 3.1 weeks, and 82% experienced complete resolution
after a median of 7.4 weeks.29 Also, 23 of 32 patients (72%) withTable 2 Interval to Resumption of Full Drug Dose in Patients With
BOLERO-2 Trial29
Variable
EVE D EXE (n [
EVE
Dose reduction or interruption events (n) 1065
Interval resumption (% of events)
1 wk 47
>1 but 2 wk 29
>2 but 3 wk 12
>3 wk 12
Interval to resumption of full dosea (days)
Median 8
Range 2-333
Abbreviations: BOLERO-2 ¼ Breast Cancer Trials of Oral Everolimus 2; EVE ¼ everolimus; EXE ¼
aFor patients able to resume the study drug.
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dian of 8.0 weeks, and 56% experienced complete resolution after a
median of 18.7 weeks.29 Finally, 27 of 32 patients (84%) with
grade  3 infections experienced resolution to grade  1 after a
median of 3.0 weeks.29
Pneumonitis is another less common but potentially serious class
toxicity associated with everolimus.15 Dose interruption with
resumption of treatment at a lower dose should be considered for
patients treated with everolimus who experience grade  2 pneu-
monitis.15,29 In the BOLERO-2 trial, 20 patients (4.1%) experienced
grade 3 pneumonitis, and 16 (80%) of these 20 patients experienced
resolution to grade  1 after a median of 3.8 weeks. Finally, 75% of
the patients with grade  3 pneumonitis experienced complete res-
olution after a median of 5.4 weeks.29 Grade  3 hyperglycemia or
new-onset diabetesmellitus developed in 28 patients (5.8%) receiving
everolimus in the BOLERO-2 trial.29 Of the patients with grade 3
hyperglycemia or new-onset diabetes mellitus, 46% experiencedDose Reductions or Dose Interruptions of Any Cause in the
482) PBO D EXE (n [ 238)
EXE PBO EXE
224 114 65
69 85 87
20 9 10
6 4 3
5 2 0
3 2 2
2-48 2-27 2-21
exemestane; PBO ¼ placebo.
Hope S. Rugoresolution to grade 1 after a median of 29.1 weeks.29 Although dose
reductions were not required for hyperglycemia in the BOLERO-2
trial,29 temporary dose interruptions are indicated for grade 3 glyce-
mic AEs.15 For grade 1 and 2 glycemic AEs, no adjustments are
indicated.15 Management recommendations include dose interrup-
tion followed by resumption of the same dose without reduction,
depending on the patient’s glucose control.
Re-escalation to the full dose of everolimus after everolimus dose
reductions for AEs was allowed on the basis of the safety ﬁndings.
Of the 181 patients with  1 everolimus dose reduction, 13 (7.2%)
were able to resume full-dose everolimus.29 Of the 13 patients who
were able to re-escalate to full-dose everolimus, 2 had required an
initial dose reduction because of pneumonitis. Of these 2 patients, 1
experienced a recurrence of this event after dose re-escalation,
resulting in discontinuation of everolimus.29 Another 4 of the 13
patients were able re-escalate to full-dose everolimus after initial
dose reductions because of stomatitis, with 2 experiencing a recur-
rence of stomatitis after dose re-escalation.29 One of the 13 patients
underwent a dose reduction because of a pruritic rash, which
recurred after dose re-escalation and necessitated discontinuation of
everolimus therapy.29 Of the 13 patients, 1 developed recurrence of
pneumonia and 1 recurrence of upper respiratory tract infection
after everolimus dose re-escalation.29 One patient initially under-
went a dose reduction because of vomiting and diarrhea but was
discontinued from treatment at a later date because of acute renal
and respiratory failure. Finally, 4 of the 13 patients who had
received an initial dose reduction for unclear reasons subsequently
were able to re-escalate to their full dose of everolimus.29
These analyses suggest that the grade 3 toxicities associated with
everolimus can be effectively managed by temporary dose in-
terruptions, with resumption of treatment at either a lower dose or
the same dose, depending on the speciﬁc toxicity. However, a few of
the patients with everolimus dose reduction because of grade 3 AEs
will be able to re-escalate to the full dose of this drug. Those with
everolimus dose re-escalation should be carefully monitored for
toxicity recurrence. However, re-escalation of the everolimus dose
after grade 3 pneumonitis is not recommended.
In clinical practice, dose interruptions, followed by dose re-
ductions as necessary, for speciﬁc grade 2 toxicities, such as sto-
matitis and pneumonitis, might allow for earlier resumption of
therapy and reduce the overall severity of the AE. It has been rec-
ommended that everolimus be withheld for grade 2 stomatitis until
resolution to grade 1, with dose reductions used for recurrent grade
2 stomatitis. Ongoing studies, including the BOLERO-4 study
(ClinicalTrials.gov identiﬁer, NCT02069093), are evaluating the
use of a prophylactic steroid mouthwash to treat everolimus-
induced stomatitis.31-33
Discontinuations Because of AEs
A greater proportion of patients treated with everolimus plus
exemestane (26% for everolimus; 9% for exemestane) than with
exemestane plus placebo (3% for exemestane; 5% for placebo)
discontinued treatment of  1 study drug because of AEs.29 The
most common all-grade AEs leading to discontinuation in the
everolimus plus exemestane treatment arm were pneumonitis
(n ¼ 27; 5.6%), stomatitis (n ¼ 13; 2.7%), dyspnea (n ¼ 11;
2.3%), fatigue (n ¼ 9; 1.9%), and rash (n ¼ 8; 1.7%).29 The grade3 or 4 AEs leading to discontinuation were pneumonitis (1.9%),
dyspnea (1.5%), stomatitis (0.8%), fatigue (0.8%), rash (0.6%),
asthenia (0.4%), and hyperglycemia (0.2%) in the everolimus plus
exemestane treatment arm and stomatitis (n ¼ 1; 0.4%) and lung
infection (n ¼ 1; 0.4%) in the exemestane plus placebo arm.29
Conclusion
Although the incidence of grade 1 to 2 AEs in the BOLERO-2
trial was greater for patients treated with everolimus plus exemes-
tane than for those who received exemestane plus placebo, the
median dose intensity of everolimus was 8.6 mg/day in patients
treated with everolimus plus exemestane despite the dose reductions
and interruptions.29 Although the mean dose and duration of
exposure were lower for patients aged  70 years than for those
aged < 70 years, everolimus plus exemestane retained similar efﬁ-
cacy in both groups.22
All grade 3 toxicities associated with everolimus should be
managed by dose interruption.26 In general, on resumption, the
dose should be reduced. Certain grade 2 toxicities, including sto-
matitis and pneumonitis, should be managed by dose interruption;
the resumption of full dosing rather than dose reduction in these
cases must be determined by the severity of the event and time to
recovery. Dose reductions for AEs can be re-escalated in some cases,
although this must be undertaken with caution and is not recom-
mended for pneumonitis. Where possible, prevention strategies
should be considered, including baseline assessment of glucose
control. A number of clinical trials are also evaluating the use of
steroid mouthwashes to treat and prevent stomatitis.
Altogether, these data suggest that oncologists treating patients
with advanced breast cancer should assess and modify the dose of
everolimus appropriately according to the severity of the observed
AE. Efﬁcacy can be maintained despite everolimus dose reductions
required to manage toxicities, such as stomatitis.28 Provider and
patient education are critical for early detection and management of
toxicity. The appropriate management of AEs will improve patient
exposure to the drug, maximize potential efﬁcacy, and control
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